The drug has been launched under the brand APATIDE in India to treat both metastatic castration sensitive prostate cancer as well as non-metastatic castration resistant prostate cancer.
The drug has been launched under the brand APATIDE in India to treat both metastatic castration sensitive prostate cancer as well as non-metastatic castration resistant prostate cancer.